ERBB2 and inflammatory breast carcinoma: It necessitates the further study of the HER2 positive IBC at the molecular level to unravel the underlying reason for its sensitivity to targeted therapy and the difference in molecular expression between IBC and the same subtype of T4-non-IBC.